"Onco-Innovations is developing ONC010, a nanoparticle-encapsulated PNKP inhibitor for cancer. The company plans to initiate first-in-human phase 1 trials in late 2026. The drug targets DNA repair pathways, aiming to exploit synthetic lethality in solid tumors."